Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28097053 | 0.84 | CNR2 (0.36) | GBA1MEN1MAPTKMT2AATM | |
| SCHEMBL25518973 | 0.83 | CNR2 (0.40) | MEN1MAPTKMT2AATMTSHR | |
| SCHEMBL28165217 | 0.83 | CACNA1H (0.32) | MEN1MAPTKMT2AATMEPHX2 | |
| SCHEMBL25284961 | 0.80 | MEN1 (0.42) | GBA1MEN1MAPTKMT2AATM | |
| SCHEMBL19267841 | 0.80 | MEN1 (0.46) | MEN1MAPTKMT2AATMACACB | |
| SCHEMBL28255026 | 0.79 | MEN1 (0.48) | MEN1MAPTKMT2AATM | |
| SCHEMBL1367746 | 0.79 | HDAC1 (0.38) | GBA1MEN1MAPTKMT2AATM | |
| SCHEMBL24700932 | 0.79 | HDAC3 (0.38) | GBA1MEN1MAPTKMT2AATM | |
| SCHEMBL17444433 | 0.77 | CNR2 (0.36) | GBA1MEN1MAPTKMT2AATM | |
| Hydrochloric Acid SCHEMBL22291356 | 0.77 | HDAC1 (0.38) | GBA1MEN1MAPTKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160356-A1 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160356-A1 | NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | GBA1 1874/4885MEN1 1308/4885MAPT 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.